TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32694949

Group type: COMPARATOR
Intervention: Apex group (Group A)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: True septum group
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: False septum group
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Multivariate model
Number of subjects: 106
Study: 32695433

Group type: EXPERIMENTAL
Intervention: Dalcroze eurhythmics program
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Simple home exercise program (SHEP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 18
Study: 32695435

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention for managing urinary incontinence in athletic women.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semi-structured interviews with health care professionals.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with participants from phase 2.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of a smartphone 'app' for adherence and monitoring of home exercises.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exploration of the impact of UI on life and sport.
Number of subjects: 0
Study: 32695577

Group type: EXPERIMENTAL
Intervention: Korean medicine treatments for LBP
Number of subjects: 150
Study: 32695923

Group type: EXPERIMENTAL
Intervention: Educational programme for blood management (non-drug intervention) in group A
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Systematic correction of perioperative iron, vitamin deficiencies, and anaemia (drug intervention) in group B
Number of subjects: 900
Study: 32695954

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program (twice a week for 3 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual standard postoperative rehabilitation
Number of subjects: 0
Study: 32695957

Group type: EXPERIMENTAL
Intervention: 100% watermelon juice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32695960

Group type: EXPERIMENTAL
Intervention: Risperidone (RIS)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Olanzapine (OLZ)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Risperidone (RIS) or Olanzapine (OLZ)
Number of subjects: 439
Study: 32696267

Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring (FGM) system
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: FreeStyle Libre™
Number of subjects: 74
Study: 32696266

Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 248

Group type: COMPARATOR
Intervention: Reference Infliximab
Number of subjects: 248
Study: 32696319

Group type: EXPERIMENTAL
Intervention: TTC-352 (180 mg twice a day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: TTC-352
Number of subjects: 15
Study: 32696441

Group type: EXPERIMENTAL
Intervention: Darunavir 600 mg q24h
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Darunavir 400 mg q24h
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Darunavir 800 mg q24h for 5 days followed by 2 days of treatment interruption
Number of subjects: 127

Group type: COMPARATOR
Intervention: Current treatment guidelines (darunavir 800 mg q24h or 600 mg q12h)
Number of subjects: 127
Study: 32696449

Group type: EXPERIMENTAL
Intervention: NOACs
Number of subjects: 279

Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 279
Study: 32696663

Group type: EXPERIMENTAL
Intervention: Antithrombotic management focusing on stroke/systemic embolism prevention, uptake of new oral anticoagulants
Number of subjects: 57149

Group type: EXPERIMENTAL
Intervention: Risk prediction tool and innovative observational studies
Number of subjects: 57149
Study: 32696697

Group type: EXPERIMENTAL
Intervention: Enriched marine oil supplement (3 escalating doses, 5-day oral administration)
Number of subjects: 20
Study: 32697509

Group type: EXPERIMENTAL
Intervention: Passive leg raising test
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Increase in central venous pressure greater than or equal to 4 mm Hg during passive leg raising
Number of subjects: 50
Study: 32697513

Group type: EXPERIMENTAL
Intervention: Venoarterial extracorporeal membrane oxygenation implantation
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Late implantation of venoarterial extracorporeal membrane oxygenation
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Preoperative left ventricular ejection fraction
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Intraoperative plasma transfusion
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Increased bilirubinemia level
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Increased creatinine levels on the day of implantation
Number of subjects: 257
Study: 32697965

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME) in high-risk patients
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by TME in clinical stages II and III patients
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Primary surgery in clinical stages II and III patients
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Primary surgery in all patients
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) in all patients
Number of subjects: 1093
Study: 32698195

Group type: EXPERIMENTAL
Intervention: Zanubrutinib 160 mg orally twice daily (n = 50)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Zanubrutinib 320 mg orally once daily (n = 23)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 77
Study: 32698532

Group type: EXPERIMENTAL
Intervention: Papaya Mosaic Virus adjuvant (30 to 240 µg) combined with trivalent influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32698642

Group type: EXPERIMENTAL
Intervention: Multiple doses of cefazolin
Number of subjects: 242179

Group type: EXPERIMENTAL
Intervention: Multiple doses of cefuroxime
Number of subjects: 242179

Group type: EXPERIMENTAL
Intervention: Single dose of cefazolin
Number of subjects: 242179

Group type: EXPERIMENTAL
Intervention: Multiple doses of cefazolin (knee)
Number of subjects: 242179

Group type: EXPERIMENTAL
Intervention: Multiple doses of cefuroxime (knee)
Number of subjects: 242179

Group type: EXPERIMENTAL
Intervention: Single dose of cefazolin (knee)
Number of subjects: 242179
Study: 32698775

Group type: EXPERIMENTAL
Intervention: One lung ventilation (OLV)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Two lung ventilation (TLV)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 302

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Invasive ventilation during general anesthesia
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Large tidal volumes and high driving pressure
Number of subjects: 302
Study: 32698814

Group type: EXPERIMENTAL
Intervention: CARE's Community Score Card© (CSC) process
Number of subjects: 0
Study: 32699021

Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy or no adjuvant treatment
Number of subjects: 182
Study: 32699163

Group type: EXPERIMENTAL
Intervention: High-risk group screening for haemoglobinopathies
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Implementation of screening in prenatal care
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Recommendation for screening among high-risk pregnant women
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Examination of adverse pregnancy outcomes
Number of subjects: 855
Study: 32699166

Group type: EXPERIMENTAL
Intervention: Neonates with COVID-19 and SARS-CoV-2 infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neonates exposed to SARS-CoV-2
Number of subjects: 0
Study: 32699580

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS) applied circumferentially after anastomosis (2.5 mL of porcine FS)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 57
Study: 32699642

Group type: EXPERIMENTAL
Intervention: Executive Functioning for Enhancing Community-based Treatment for ASD (EFFECT for ASD)
Number of subjects: 0
Study: 32699643

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 1 g at the start and end of surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for TXA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral rosuvastatin 40 mg before and 20 mg daily for 30 days after surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for rosuvastatin
Number of subjects: 100
Study: 32699645

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral treatment for gambling
Number of subjects: 0
Study: 32699648

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome (PRO)-measures as a dialogue tool in patient-physician consultations
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Patient involvement in research (PPI)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Co-creation in analysis
Number of subjects: 5
Study: 32699908

Group type: EXPERIMENTAL
Intervention: Systolic septal rebound stretch (SRSsept)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: SRSsept
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: SRSsept and ApRock
Number of subjects: 200
Study: 32699926

Group type: EXPERIMENTAL
Intervention: Breast-Conserving Therapy (BCT) with whole-breast radiation
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: BREAST-Q satisfaction score at 6 months post-radiation
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: BREAST-Q satisfaction score at 3 years post-surgery
Number of subjects: 216
Study: 32699996

Group type: EXPERIMENTAL
Intervention: MRI measured fat fraction (FF)
Number of subjects: 33
Study: 32700065

Group type: EXPERIMENTAL
Intervention: 100 mg AG-221 oral dose
Number of subjects: 6
Study: 32700114

Group type: EXPERIMENTAL
Intervention: Integrated osteoporosis care (IOC) programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 0
Study: 32700139

Group type: EXPERIMENTAL
Intervention: Cxbladder Monitor (low-probability result)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Cxbladder Monitor (elevated-probability result)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Overall management with Cxbladder Monitor
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Overall procedures ordered for low-probability patients
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Invasive procedures for elevated-probability patients
Number of subjects: 828
Study: 32700140

Group type: EXPERIMENTAL
Intervention: Prophylactic ectoine mouthwash
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Active ectoine mouthwash
Number of subjects: 45

Group type: COMPARATOR
Intervention: Calcium phosphate mouthwash
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ectoine mouthwash (both prophylactic and active)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ectoine mouthwash
Number of subjects: 45
Study: 32700260

Group type: EXPERIMENTAL
Intervention: MenB-FHbp vaccine
Number of subjects: 3989

Group type: COMPARATOR
Intervention: Control (hepatitis A virus vaccine/saline or saline)
Number of subjects: 3989
Study: 32700543

Group type: EXPERIMENTAL
Intervention: On-demand high-sensitivity troponin I (Abbott Architect) measurements using fresh blood samples
Number of subjects: 937

Group type: COMPARATOR
Intervention: Batch-wise high-sensitivity troponin T (Roche) measurements using frozen blood samples
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Overall on-demand and batch-wise measurements of high-sensitivity troponin
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Rapid diagnostic algorithms
Number of subjects: 937
Study: 32700765

Group type: EXPERIMENTAL
Intervention: Patients with hormone receptor (HR) positive metastases
Number of subjects: 3295

Group type: EXPERIMENTAL
Intervention: Patients with ER conversion from negative to positive
Number of subjects: 3295

Group type: EXPERIMENTAL
Intervention: Patients with PR remained positive
Number of subjects: 3295

Group type: EXPERIMENTAL
Intervention: Patients with PR conversion
Number of subjects: 3295
Study: 32701364

Group type: EXPERIMENTAL
Intervention: Active-Fixation Atrial Leads
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32701367

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32701411

Group type: EXPERIMENTAL
Intervention: CD30.CAR-Ts after lymphodepletion with fludarabine-based regimen
Number of subjects: 41
Study: 32701541

Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (ESI) for leg pain
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Facet interventions for low back pain
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Sacroiliac joint (SIJ) injections
Number of subjects: 318
Study: 32701811

Group type: EXPERIMENTAL
Intervention: F-fluciclovine PET/CT
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Biopsy of the mediastinal mass
Number of subjects: 1
Study: 32701818

Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-46 PET/CT
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Robotic-assisted Ivor-Lewis esophagectomy
Number of subjects: 1
Study: 32702087

Group type: EXPERIMENTAL
Intervention: Myocardial injury diagnosed according to the peak troponin I in relation to the upper reference limit (URL, 99th centile) using Abbott Architect troponin I assay.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multisystem, multimodality imaging including multiparametric, stress perfusion, cardiovascular magnetic resonance imaging, and computed tomography coronary angiography at 28 days post-discharge.
Number of subjects: 0
Study: 32702120

Group type: EXPERIMENTAL
Intervention: Targeted metagenomics using strand-specific libraries with target enrichment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: RSV-A
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: RSV-B
Number of subjects: 17
Study: 32702156

Group type: EXPERIMENTAL
Intervention: Endovascular interventions (angioplasty 95, stenting 26)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Endovascular interventions
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Peri-interventional dual antiplatelet therapy (DAPT)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Concurrent surgery
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Technical failure
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Retinopathy secondary to hypertension
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pulmonary artery hypertension (PAH)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Interventions on mid-aorta stenosis (MAS) or renal artery stenosis (RAS)
Number of subjects: 101
Study: 32702336

Group type: EXPERIMENTAL
Intervention: Patients with TBI
Number of subjects: 13138
Study: 32702410

Group type: EXPERIMENTAL
Intervention: Intervention group (survivors of OHCA with GCS ≥12)
Number of subjects: 139
Study: 32702570

Group type: EXPERIMENTAL
Intervention: Durvalumab 10 mg/kg every 2 weeks
Number of subjects: 444
Study: 32702685

Group type: EXPERIMENTAL
Intervention: Normalized gradient field function
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cross correlation, mutual information, and gradient methods
Number of subjects: 0
Study: 32702810

Group type: EXPERIMENTAL
Intervention: Tongue imaging using automatic tongue diagnosis system
Number of subjects: 67
Study: 32702903

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting stent implantations in dialysis patients
Number of subjects: 6791

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting stent implantations in CKD patients
Number of subjects: 6791

Group type: COMPARATOR
Intervention: Polymer-free sirolimus-eluting stent implantations in patients with normal renal function (NRF)
Number of subjects: 6791
Study: 32703167

Group type: EXPERIMENTAL
Intervention: Cochlear implant rehabilitation
Number of subjects: 100
Study: 32703186

Group type: EXPERIMENTAL
Intervention: Dietary habits and their association with cognitive function, gut microbiota composition, and brain measures.
Number of subjects: 683

Group type: COMPARATOR
Intervention: Clinical evaluation including neurological examination and MRI scanning for individuals with confirmed Mild Cognitive Impairment (MCI).
Number of subjects: 683
Study: 32703235

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated gel dressing (gel-dress)
Number of subjects: 3483

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated gel dressing (gel-dress) with CHG skin antisepsis
Number of subjects: 3483
Study: 32703509

Group type: EXPERIMENTAL
Intervention: Fluorine-18 flurpiridaz PET
Number of subjects: 795

Group type: COMPARATOR
Intervention: Technetium-99m-labeled SPECT
Number of subjects: 795
Study: 32703550

Group type: EXPERIMENTAL
Intervention: QoR-15K (postoperative)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: QoR-15K (preoperative)
Number of subjects: 193
Study: 32703556

Group type: EXPERIMENTAL
Intervention: Intramural needle ablation at IES sites
Number of subjects: 26
Study: 32703590

Group type: EXPERIMENTAL
Intervention: Risk model incorporating clinical, angiographic, and physiological parameters
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Risk model with clinical risk factors alone
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Risk model with clinical risk factors and angiographic parameters
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Risk model incorporating clinical, angiographic, and physiological predictors
Number of subjects: 2200
Study: 32703690

Group type: EXPERIMENTAL
Intervention: Food Secure (FS)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Low Food Security (low FS)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Very Low Food Security (very low FS)
Number of subjects: 579
Study: 32704173

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily and Lenalidomide 25 mg daily
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Everolimus and Lenalidomide combination
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PD assessment
Number of subjects: 44
Study: 32704381

Group type: EXPERIMENTAL
Intervention: Prolonged strenuous exercise training
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Comprehensive data collection including anthropometry, resting electrocardiography, echocardiography, blood sampling, retinal vessel diameters, carotid sonography, and cardiopulmonary exercise testing
Number of subjects: 277
Study: 32704557

Group type: EXPERIMENTAL
Intervention: THEMIS-like cohort (ticagrelor plus acetylsalicylic acid)
Number of subjects: 125830

Group type: EXPERIMENTAL
Intervention: CAD-T2D cohort (placebo plus acetylsalicylic acid)
Number of subjects: 125830

Group type: COMPARATOR
Intervention: Both cohorts
Number of subjects: 125830

Group type: EXPERIMENTAL
Intervention: THEMIS-like cohort
Number of subjects: 125830

Group type: EXPERIMENTAL
Intervention: CAD-T2D cohort
Number of subjects: 125830
Study: 32705337

Group type: EXPERIMENTAL
Intervention: DMEK with easy unfolding and attachment (Group I)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: DMEK with moderate difficulty (Group II)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: DMEK with high difficulty (Group III)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: DMEK with very high difficulty (Group IV)
Number of subjects: 169
Study: 32705923

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (pola) + bendamustine-rituximab (BR) at 1.8 mg/kg pola, every 3 weeks for six cycles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polatuzumab vedotin (pola)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bendamustine-obinutuzumab (BG)
Number of subjects: 0
Study: 32706437

Group type: EXPERIMENTAL
Intervention: C-SSRS (Columbia-Suicide Severity Rating Scale) during ED visit
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: History of prior SA as measured by C-SSRS
Number of subjects: 1376
Study: 32706533

Group type: EXPERIMENTAL
Intervention: Bacterial strains obtained from children with EED
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Fecal microbiota from children with EED
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Gnotobiotic mice colonized with cultured duodenal strains from children with EED
Number of subjects: 110
Study: 32706636

Group type: EXPERIMENTAL
Intervention: CTS5 high-risk group
Number of subjects: 7486

Group type: EXPERIMENTAL
Intervention: CTS5 intermediate-risk group
Number of subjects: 7486

Group type: EXPERIMENTAL
Intervention: CTS5 low-risk group
Number of subjects: 7486

Group type: EXPERIMENTAL
Intervention: CTS5 high-risk patients
Number of subjects: 7486
Study: 32706652

Group type: EXPERIMENTAL
Intervention: mHealth group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: paper diary group
Number of subjects: 26

Group type: COMPARATOR
Intervention: control group (standard of care)
Number of subjects: 26
Study: 32706656

Group type: EXPERIMENTAL
Intervention: Text message survey
Number of subjects: 17
Study: 32706702

Group type: EXPERIMENTAL
Intervention: mRehab (smartphone app with 3D printed objects)
Number of subjects: 16
Study: 32706719

Group type: COMPARATOR
Intervention: Health education podcast app (listened to ~60 min/week for 12 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Health education podcast app
Number of subjects: 96
Study: 32706720

Group type: EXPERIMENTAL
Intervention: Breathe (ICBT with ad hoc telephone and email support)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (static webpage listing anxiety resources)
Number of subjects: 94
Study: 32706891

Group type: EXPERIMENTAL
Intervention: Treosulfan-based conditioning (TREO, fludarabine, 2 Gy total-body irradiation)
Number of subjects: 130
Study: 32707340

Group type: EXPERIMENTAL
Intervention: Hepatic steatosis
Number of subjects: 3756

Group type: COMPARATOR
Intervention: No hepatic steatosis
Number of subjects: 3756
Study: 32709042

Group type: EXPERIMENTAL
Intervention: Invasive lobular carcinoma (ILC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invasive ductal carcinoma of no special type (NST)
Number of subjects: 0
Study: 32709218

Group type: EXPERIMENTAL
Intervention: Early-stage ADPKD treatment options (specific treatment details not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discrete Choice Experiment (DCE)
Number of subjects: 0